Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: David Graham who wrote (7732)	9/25/2001 10:30:42 PM
From: Montana Wildhack	Read Replies (2) \| Respond to of 14101

David, Great info on one of our formerly unstoppable competitors. I particularly found the reference to naproxen's blood thinning aspect in a test of pain killing abilities interesting. I fail to understand why this would not have been dealt with upfront in the results publication. That is, since the scientists involved understood that naproxen has both affects, why wouldn't they review and publish the original data showing naproxen's safety variance to a placebo for heart attacks. They could have compared that data to the heart attack variance found in their own study and published that in the results thus addressing the decreased rate of heart attacks in the naproxen group. Thanks Celebrex and Vioxx for expanding the market so much that finally the dangers of NSAID's is starting to come out including on CNBC and ROBTV. If only there was a safer way to achieve relief from arthritis pain. Ideally something proven as effective as the current dangerous NSAID's but also proven to be safe. Yet all competitors except the walking dead are aware of Pennsaid and there is no apparent real interest in us. I suspect that will change dramatically soon after the FDA approval which we have waited long for and which Rebecca 'with great comfort and great confidence' assured us we will get on ROBTV. No need to squander capital when you can wait until its a winner. Besides its discounted nicely by the currency. I can't help myself betting we will have at least one material NR before the AGM and perhaps even more importantly a freshly published quarterly report. The expectation is that both the EU status and the EU partner situation will have been publicly addressed by then at a minimum. What a life. Wolf